Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 308

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 308
---
 repayment costs impacting the collaboration liabilities,

(iv) obtaining and reconciling the key operational documents like related clinical projects budgets with the accounting memos provided by Management,

(v) verifying that the note to the consolidated financial statements “13.1- Revenue from collaboration and licensing agreements” is appropriate.

/s/ Deloitte & Associés PricewaterhouseCoopers

Paris la Défense, France Neuilly-sur-Seine, France

Deloitte & Associés and PricewaterhouseCoopers Audit have served as the Company’s auditor since 2014 and 2024, respectively.

F-4

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of Innate Pharma S. A.

Opinion on the Financial Statements

We have audited the accompanying statements of financial position of Innate Pharma S. A. and its subsidiary (the “ Company”) as of December 31, 2023 and 2022, the related consolidated statements of income (loss), comprehensive income (loss), change in shareholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are